[12] Patent
[11] Patent No.:GC0007482  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125280
Date of the Decision to Grant the Patent:01/Apr/2018

[21] Application No.:GC 2013-25022

[22] Filing Date:25/7/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
26/7/2012
4/6/2013
61/676,134
61/830,911

[72] Inventors:1- Giordano Caponigro،2- Darrin Stuart،3- Sunkyu Kim،4- Alice Loo،5- Scott Delach

[73] Owner: Novartis AG, Lichtstrasse 35, 4056, Basel, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4184, 31/506, 31/519; A61P 35/00 (2006.01)

[56] Cited Documents:

-E. HUILLARD ET AL: Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy, PROC EEO I NGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 22, 14 May 2012
-WO 2005/094830 Al (PFIZER PROD INC [US]; ECK STEPHEN LOUIS [US]; FRY DAVID WILLIAM [US];) 13 October 2005
-ZHAO Y ET AL: Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition
and apoptosis, BIOCHEMICAL AND BIOPHYSICAL RESEARCH
COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US,
vol. 370, no. 3, 06 June 2008
-T. C. TORTELLI ET AL: Abstract 5598: Interaction between BRAF inhibitor PLX-4720 and CDK inhibitors can sensitize melanoma cells with BRAF V600E mutation, CANCER RESEARCH, vol. 72, no. 8 Supplement, 15 April 2012
-LI JING ET AL: Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells., CANCER INVESTIGATION MAY 2010, vol. 28, no. 04 May 2010
 
Examiner: PH. Mohammad S. AlMousa

[54] PHARMACEUTICAL COMBINATIONS OF A CDK4/6 INHIBITOR AND A B-RAF INHIBITOR
[57] Abstract: A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
No. of claims: 14     No. of figures: 1


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.